CellCentric is a research driven and patient-centric clinical stage, private biotechnology company pioneering small molecule inhibition of the twin proteins, p300/CBP. We are focused on the rapid development of inobrodib, a first-in-class small molecule p300/CBP inhibitor, which has the potential to benefit patients with many different cancer indications.
CellCentric is a privately held, UK company with Morningside Ventures as its majority shareholder. Earlier funding came from Providence Investment Company, Takeda Ventures, UK Innovation Science & Seed Fund, Avlar, NESTA and the University of Cambridge.
CellCentric has also benefited from significant non-dilutive financial awards, including from UKRI/Innovate UK.